The correlation of drug sensitivity with cMet protein expression motivated us to compare Plk1 inhibitor sensitivity [area under the curve (AUC) and effective dose 50 (ED50)] to MET gene copy number in NSCLC cell lines. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.